Categoria: Letteratura

Home / Letteratura
Interim analysis from ELEANOR: a multi-national, prospective, noninterventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine
Articolo

Interim analysis from ELEANOR: a multi-national, prospective, noninterventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

Autori: Bartsch R, et al. Background: Recent advances in the treatment of human epidermal growth factor receptor positive (HER2+) early breast cancer (eBC) have led to a reduction in recurrence risk; still a relevant percentage of patients relapses over time, predominantly presenting with distant recurrence. Neratinib is registered in Europe as extended adjuvant treatment for...

Translational Breast Cancer Research Consortium Trial 022: neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases
Articolo

Translational Breast Cancer Research Consortium Trial 022: neratinib and trastuzumab-emtansine for HER2+ breast cancer brain metastases

Autori: Freedman R, et al. Purpose: Treatment options for patients (pts) with HER2+ BCBM remain limited. We previously reported that neratinib monotherapy is associated with a volumetric central nervous system objective response rate (CNS ORR) of 8%, whereas the combination of neratinib and capecitabine resulted in a volumetric CNS ORR of 49% (in lapatinib-naïve pts)....

Genomic analysis of circulating tumor DNA from patients with HR+, HER2-mutant metastatic breast cancer enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab
Articolo

Genomic analysis of circulating tumor DNA from patients with HR+, HER2-mutant metastatic breast cancer enrolled in SUMMIT: mechanisms of acquired resistance to neratinib + fulvestrant + trastuzumab

Autori: Ma C, et al. Background: HER2 activating mutations occur in 2-5% of metastatic breast cancer (MBC) patients. These mutations cluster in the kinase domains and at amino acids 309-310 in the extracellular domain. The MutHER, SUMMIT, and PlasmaMATCH clinical trials have shown neratinib monotherapy or neratinib plus fulvestrant combination produce clinical benefit in 28%...

Pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer: primary results from the POSITIVE trial 
Articolo

Pregnancy outcome and safety of interrupting therapy for women with endocrine responsIVE breast cancer: primary results from the POSITIVE trial 

Autori: Partridge A, et al. Background: Pregnancy after breast cancer (BC) is of substantial importance for many young women at diagnosis and during follow-up. BC treatment including standard endocrine therapy (ET) (5-10 years) may reduce ovarian reserve and the chances of subsequent successful pregnancy, given conception is contraindicated during ET. A temporary interruption of ET...

A phase 1b study of neratinib with THP in metastatic and locally advanced breast  cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast  cancer (IBC), and neratinib with taxol followed by AC in HR+ /HER2- IBC
Articolo

A phase 1b study of neratinib with THP in metastatic and locally advanced breast cancer, and phase II study of THP followed by AC in HER2 + primary inflammatory breast cancer (IBC), and neratinib with taxol followed by AC in HR+ /HER2- IBC

Autori: Marx AN, et al. Background: The pathologic complete response (pCR) rate in inflammatory breast cancer (IBC) patients is worse than in non-IBC patients; new drug combinations are warranted to improve pCR rates across all IBC molecular subtypes. Based on our preclinical data, we added neratinib to standard neoadjuvant chemotherapy in both HER2+ (synergy) and...

Retinoic acid receptor signalling plays a role in neratinib  resistance in HER2+ breast cancer cell lines
Articolo

Retinoic acid receptor signalling plays a role in neratinib  resistance in HER2+ breast cancer cell lines

Autori: O’Reilly R, et al. Introduction: NER is a pan-HER tyrosine kinase inhibitor (TKI) approved for the treatment of HER2+ BC in the adjuvant setting following trastuzumab and in combination with capecitabine for advanced disease. Resistance to small molecule TKIs like NER can develop in the clinic. Pre-clinical studies have highlighted that retinoic acid can...

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
Articolo

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

Autori: Hurvitz SA, Hegg R, Chung WP, et al. Background: An improvement in progression-free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer in the progression-free survival interim analysis of the DESTINY-Breast03 trial. The aim of DESTINY-Breast03 was to compare the efficacy and safety of trastuzumab deruxtecan versus...

Neratinib vs. trastuzumab plus ribociclib in ERBB2-positive breast cancer: preclinical mechanistic efficacy study
Articolo

Neratinib vs. trastuzumab plus ribociclib in ERBB2-positive breast cancer: preclinical mechanistic efficacy study

Autori: Koirala N, et al. Background: Despite the wide-ranging clinical success of human epidermal growth factor receptor 2 (HER2)-directed therapies, many HER2-positive breast cancer patients eventually progress because of the development of primary or acquired resistance. PIK3CA is found often mutated in breast cancer (>30%, TCGA dataset) and responsible for HER2-directed treatment failure. Purpose: Inhibition...

Efficacy and safety of the addition of internal mammary irradiation to standard adjuvant radiation in early-stage breast cancer: a systematic review and meta-analysis
Articolo

Efficacy and safety of the addition of internal mammary irradiation to standard adjuvant radiation in early-stage breast cancer: a systematic review and meta-analysis

Autori: Korzets Yasmin, et al. Background: Adjuvant regional nodal irradiation together with whole breast or chest wall irradiation is considered standard of care in most node positive early breast cancer. Existing data on adding internal mammary irradiation (IMNI) to the regional nodal fields are inconsistent. The objective of this study was to conduct a meta-analysis...